Nieuws

BenefitsPRO1u
Cigna now offers employers $200 Wegovy, Zepbound copay option
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...
Novo cuts Wegovy cost to $199
For a limited time, Wegovy will be available to new patients at $199 for the first month, Novo Nordisk said Thursday.
Investing Snacks14u
Hims & Hers Trips as Cigna Curbs Drug Costs
Hims & Hers stock took a nosedive after Cigna’s Evernorth division announced a $200 monthly cap on popular weight-loss drugs ...
Healthcare Dive19u
Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
Investing.com20u
Hims & Hers biedt Wegovy aan tegen nieuwe toegankelijke prijs
SAN FRANCISCO - Hims & Hers Health, Inc. (NYSE: HIMS), een toonaangevend gezondheids- en wellnessplatform, heeft een nieuwe prijsoptie aangekondigd voor Wegovy®, een voorgeschreven behandeling tegen o ...
The American Journal of Managed Care21u
Evernorth Launches Co-Pay Cap for Weight Loss Drugs Amid New Federal Drug Pricing Effort
Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...
Stocktwits on MSN23u
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull
Shares of telehealth provider Hims & Hers Health Inc. (HIMS) dropped over 3% on Thursday after Cigna Group’s (CI) Evernorth ...
Cigna is putting a cap on weight loss drug costs
Photo: Scott Olson () Getting access to popular weight loss drugs will be simpler and cheaper for some. Health insurer Cigna ...
Investing.com23u
Citi handhaaft verkoopadvies voor Hims & Hers met koersdoel van $ 30
Citi-analist Daniel Grosslight handhaafde donderdag zijn verkoopadvies voor Hims & Hers Health, Inc. (NYSE: HIMS) met een ongewijzigd koersdoel van $ 30,00. Dit besluit volgt op het nieuws dat NovoCar ...